Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Avonex Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG218

    Avonex (interferon beta-1a) Coverage Criteria

    Customize your policy alerts

    Sign up for Oscar Health Policy PG218 alerts

    Get alerted when Policy PG218 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs prior authorization and medical necessity review for Avonex (interferon beta-1a) for pediatric and adult members with multiple sclerosis or clinically isolated syndrome. It defines initial and continuation criteria, quantity limits, documentation requirements, and non-covered uses.

    Policy Summary
    PayerOscar Health
    PolicyAvonex (interferon beta-1a) Coverage Criteria
    Policy CodePolicy PG218
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation supporting the applicable initial or continuation criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30 mcgrecommended intramuscular dose once weekly
    4prefilled syringes or autoinjectors allowed per 28 days
    12 monthsmaximum authorization period
    18 yearsage threshold for adult criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    covered adult disease presentations

    Coverage Criteria

    General Medical Necessity

    Covered when ONE of the following criteria is met:

    General medical necessity

    • Pediatric exception: Member is younger than 18 years of age and has multiple sclerosis, with documentation that the benefits outweigh the risks.Under 18 years

      If approved, authorization may continue until the member reaches age 18.

    • Adult clinical review: Member meets the applicable initial clinical review or subsequent clinical review criteria.

    Initial Therapy for Adult Multiple Sclerosis

    Covered when ALL of the following are met:

    Initial therapy for adult multiple sclerosis

    • Qualified prescriber: Prescribed by or in consultation with a neurologist or physician who specializes in the treatment of multiple sclerosis.
    • Adult age: Member is 18 years of age or older.18 years or older
    • Covered MS presentation

      • Relapsing-remitting MS: Member has relapsing-remitting multiple sclerosis (RRMS).
      • Active secondary progressive MS: Member has active secondary progressive multiple sclerosis (SPMS).
      • Clinically isolated syndrome:

    Continuation Therapy for Adult Multiple Sclerosis

    Covered when ALL of the following are met:

    Continuation therapy for adult multiple sclerosis

    • Qualified prescriber: Avonex is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis.
    • Treatment response

      • Objective improvement

        • MRI disease activity: Reduced disease activity on MRI.
        • Disability scores: Improved or stable disability scores.

    Avonex is not covered when used in combination with another disease-modifying therapy for multiple sclerosis. The policy notes limited knowledge regarding combined disease-modifying therapies for MS.

    Avonex is not covered for non-relapsing forms of multiple sclerosis, including primary progressive multiple sclerosis. The safety and efficacy of Avonex have not been established in patients with primary progressive MS.

    Avonex is not covered for neurological conditions unrelated to multiple sclerosis, including conditions such as Alzheimer’s disease. The policy does not identify sufficient high-quality evidence supporting its safety and efficacy for these uses.

    Avonex is not covered as a treatment for cancer or as an adjunct to cancer therapy. The policy states that the National Comprehensive Cancer Network does not support interferon beta products for management of malignancies.

    Avonex is not covered for viral infections, including chronic viral hepatitis. Although interferon products may be used for viral hepatitis, interferon beta products are not approved for management of these conditions.

    Avonex is not covered for autoimmune disorders unrelated to multiple sclerosis, including Crohn’s disease and ulcerative colitis. The policy cites conflicting efficacy results and a lack of high-quality evidence supporting the safety and efficacy of interferon products for these disorders.

    Any Avonex indication or use that does not meet the policy criteria is considered experimental, investigational, unproven, or not medically necessary and is not covered by the Plan.

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Avonex (interferon beta-1a). Authorization may be granted for pediatric members younger than 18 with multiple sclerosis when documentation shows that benefits outweigh risks, or when the applicable adult initial or subsequent clinical review criteria are met.

    • Pediatric exception: If approved, authorization may continue until the member reaches 18 years of age.
    • Adult initial review: The member must meet the applicable initial clinical review criteria.
    • Subsequent review: The member must meet the applicable continuation clinical review criteria.
    Documentation Required

    Clinical Records Supporting Medical Necessity

    Submit clinical records supporting medical necessity for the requested therapy. Documentation includes up-to-date chart notes and relevant test results and/or imaging reports supporting the diagnosis and treatment request.

    Multiple Sclerosis Background

    Multiple sclerosis is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system with relapsing and progressive forms. Avonex (interferon beta-1a) is a first-generation disease-modifying therapy administered by intramuscular injection once weekly. This policy addresses coverage for relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    Policy Definitions

    Clinically isolated syndrome
    DefinitionA first episode of neurologic symptoms caused by inflammation or demyelination in the central nervous system.
    DurationThe neurologic symptoms last at least 24 hours.
    Clinical significanceClinically isolated syndrome is a qualifying form of multiple sclerosis presentation under the adult initial review criteria.
    Disease-modifying therapy
    DefinitionA medication that modifies the course of multiple sclerosis.
    Effect on relapsesReduces relapses.
    Effect on disability

    Initial Authorization

    Initial Authorization

    Initial therapy is covered when the applicable pathway criteria are met:

    Initial authorization pathways

    • Pediatric pathway: Member is younger than 18 years of age, has multiple sclerosis, and documentation indicates that the benefits outweigh the risks.Under 18 years

      If approved, authorization may continue until the member reaches age 18.

    • Adult pathway

      • Qualified prescriber: Prescribed by or in consultation with a neurologist or physician who specializes in the treatment of multiple sclerosis.
      • Covered MS presentation

    Continuation Authorization

    Continuation Authorization

    Continuation is covered when ALL of the following are met:

    Continuation authorization

    • Specialist prescribing: Avonex is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis.
    • Treatment response

      • Objective improvement

        • MRI disease activity: Reduced disease activity on MRI.
        • Disability scores: Improved or stable disability scores.

    Quantity Limits

    Avonex quantity limit
    Quantity limit4 prefilled syringes or autoinjectors.
    Limit periodPer 28 days.
    Recommended dose30 mcg injected intramuscularly once weekly.
    Policy Summary
    PayerOscar Health
    PolicyAvonex (interferon beta-1a) Coverage Criteria
    Policy CodePolicy PG218
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation supporting the applicable initial or continuation criteria.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationMultiple Sclerosis BackgroundPolicy DefinitionsInitial AuthorizationContinuation AuthorizationQuantity Limits
    Member has clinically isolated syndrome (CIS).
  1. Monotherapy: Avonex will be used as monotherapy for multiple sclerosis; the member is not using and will not use other disease-modifying MS therapies while receiving Avonex.No concurrent MS disease-modifying therapy
  2. Appropriate dose and frequency: Avonex is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.
  3. Quantity limit: The requested medication is used within the Plan's quantity limit.4 prefilled syringes or autoinjectors per 28 days

    The recommended dose is 30 mcg injected intramuscularly once weekly.

  4. Relapse rate: Reduced relapse rate.
  5. Fatigue or walking assessments: Improved fatigue or walking assessments.
  6. MS symptom stabilization or improvement

    • Motor function stabilized or improved.
    • Fatigue stabilized or improved.
    • Vision stabilized or improved.
    • Bowel or bladder function stabilized or improved.
    • Spasticity stabilized or improved.
    • Walking or gait stabilized or improved.
    • Pain, numbness, or tingling stabilized or improved.
    • Provide recent clinical chart documentation supporting the diagnosis and medical necessity.
    • Include relevant test results and imaging reports, when applicable.
    • Prescription claims records or receipts may support prior trials of formulary alternatives when required.
    Documentation Required

    Initial Review Documentation Recency

    For adult initial review, the clinical chart documentation submitted to support medical necessity must be recent and dated within the preceding 3 months.

    • Documentation must indicate the member meets all applicable initial criteria.
    • Adult initial criteria include specialist involvement, age 18 or older, a qualifying MS form, monotherapy use, and dosing supported by labeling, compendia, or evidence-based guidelines.
    Documentation Required

    Continuation Review Documentation Recency

    For continuation review, submit clinical documentation dated within the preceding 6 months. The records must show treatment response or stability, including improvement or stabilization in an objective measure or MS symptom.

    • Documentation must confirm prescribing by or consultation with a neurologist or physician specializing in multiple sclerosis.
    • Show improvement in an objective measure, such as MRI disease activity, disability scores, relapse rate, fatigue, or walking assessment; or stabilization/improvement in an MS symptom.
    • If continuation criteria are met, the product may be authorized for up to 12 months.
    Denial Risk

    Non-Covered or Unproven Uses

    Avonex is not medically necessary for uses considered experimental, investigational, unproven, or otherwise outside the policy criteria. Claims may be denied for the following non-covered indications and uses.

    • Use in combination with other disease-modifying therapies for multiple sclerosis.
    • Treatment of non-relapsing forms of multiple sclerosis, including primary progressive MS.
    • Treatment of neurological conditions unrelated to multiple sclerosis, such as Alzheimer's disease.
    • Treatment of cancer or use as an adjunct to cancer therapies.
    • Treatment of viral infections, including chronic viral hepatitis.
    • Management of autoimmune disorders unrelated to multiple sclerosis, including Crohn's disease or ulcerative colitis.
    Slows disability progression.
    Relapsing-remitting MS
    DefinitionA disease course characterized by clearly defined attacks of new or increasing neurologic symptoms.
    Recovery patternAttacks are followed by periods of partial or complete recovery.
    Policy relevanceRelapsing-remitting MS is one of the qualifying disease presentations for adult initial review.
    Secondary progressive MS
    DefinitionA disease course following relapsing-remitting MS.
    Disease patternProgressive worsening of neurologic function over time.
    RelapsesThe progressive worsening may occur with or without relapses.
    Primary progressive MS
    DefinitionWorsening neurologic function from the onset of symptoms.
    Early courseOccurs without early relapses or remissions.
    Coverage distinctionPrimary progressive MS is a non-relapsing form of multiple sclerosis and is not a qualifying adult presentation for initial Avonex review.
    Relapse
    DefinitionThe appearance of new symptoms or worsening of existing symptoms.
    Duration requirementSymptoms must last at least 24 hours.
    ExclusionThe symptoms must occur in the absence of fever or infection.
    No evidence of
    MeaningThe reviewer has not identified records of the specified item or condition within the submitted materials or claims history.
    When evidence is absentIn the absence of such evidence, the member is considered eligible.
    When evidence is presentIf evidence of the item or condition is present upon review, the member does not qualify.
    Documentation
    Chart informationUp-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses.
    Formulary-trial supportPrescription claims records and/or prescription receipts to support prior trials of formulary alternatives.
    FormatDocumentation is written information supporting the diagnosis or applicable clinical criteria.
  7. One qualifying form

    • Relapsing-remitting MS: Member has relapsing-remitting multiple sclerosis (RRMS).
    • Active secondary progressive MS: Member has active secondary progressive multiple sclerosis (SPMS).
    • Clinically isolated syndrome: Member has clinically isolated syndrome (CIS).
  8. Monotherapy: Avonex will be used as monotherapy for multiple sclerosis; the member is not using and will not use other disease-modifying MS therapies while receiving Avonex.No concurrent MS disease-modifying therapy
  9. Appropriate dose and frequency: Avonex is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.
  10. Quantity limit: The requested medication is used within the Plan's quantity limit.4 prefilled syringes or autoinjectors per 28 days

    The recommended dose is 30 mcg injected intramuscularly once weekly.

  11. Relapse rate: Reduced relapse rate.
  12. Fatigue or walking assessments: Improved fatigue or walking assessments.
  13. MS symptom stabilization or improvement

    • Motor function stabilized or improved.
    • Fatigue stabilized or improved.
    • Vision stabilized or improved.
    • Bowel or bladder function stabilized or improved.
    • Spasticity stabilized or improved.
    • Walking or gait stabilized or improved.
    • Pain, numbness, or tingling stabilized or improved.